Effects of the CB1 receptor antagonists AM6545 and AM4113 on metabolic syndrome-induced prostatic hyperplasia in rats
Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
Department of Pharmacology, Faculty of Veterinary Medicine, Kafrelsheikh University, Kafrelsheikh, Egypt
Department of Anatomy and Embryology, Faculty of Veterinary Medicine, Kafrelsheikh University, Kafrelsheikh, Egypt
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt
Center for Drug Discovery, Northeastern University, Boston, MA, USA
Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, MA, USA
Abstract
Metabolic syndrome (MetS) is a combination of metabolic disorders that can predispose individuals to benign prostatic hyperplasia (BPH). The inhibition of the cannabinoid 1 (CB1) receptor has been used to treat metabolic disorders in animal models. This study reports the use of a peripherally restricted CB1 antagonist (AM6545) and a neutral CB1 antagonist (AM4113) to improve MetS-related BPH in rats. Animals were divided into three control groups to receive either a normal rodent diet, AM6545, or AM4113. MetS was induced in the fourth, fifth, and sixth groups using a concentrated fructose solution and high-salt diet delivered as food pellets for eight weeks. The fifth and sixth groups were further given AM6545 or AM4113 for additional four weeks. Body and prostate weights were measured and prostate sections were stained with hematoxylin eosin. Cyclin D1, markers of oxidative stress and inflammation, and levels of the endocannabinoids were recorded. BPH in rats with MetS was confirmed through increased prostate weight and index, as well as histopathology. Treatment with either AM6545 or AM4113 significantly decreased prostate weight, improved prostate histology, and reduced cyclin D1 expression compared with the MetS group. Groups treated with CB1 antagonists experienced reduced lipid peroxidation, recovered glutathione depletion, restored catalase activity, and had lower inflammatory markers interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α). MetS rats treated with either AM6545 or AM4113 showed reduced concentrations of anandamide (AEA) and 2-arachidonoylglycerol (2-AG) in the prostate compared with the MetS group. In conclusion, the CB1 antagonists AM6545 and AM4113 protect against MetS-induced BPH through their anti-proliferative, antioxidant, and anti-inflammatory effects.
Untitled section
Keywords: AM6545, AM4113, prostate, cannabinoid antagonist, metabolic syndrome (MetS).
Article notes
Untitled section
Received 2023 Apr 11; Accepted 2023 May 19; Revised 2023 May 16; Issue date 2023 Dec 1.
Introduction
Benign prostatic hyperplasia (BPH) is a common histologic finding in aging men and refers to nonmalignant development or hyperplasia of prostatic tissue [1]. It is an important cause of lower urinary tract symptoms, such as weak urinary stream, impaired bladder emptying, post-void dribbling, and the sensation of incomplete bladder emptying after voiding [2]. As reported by the American Urological Association, the prevalence of BPH is over 50% in men over 60 years of age and increases to 90% in men over 80 years of age [3]. Although the mechanism of BPH development remains unclear, multiple risk factors have been suggested, such as aging, inflammation, direct infection, and oxidative stress [2]. In addition, recent studies have demonstrated a clear association between BPH and metabolic syndrome (MetS) [4–7].
MetS is a combination of metabolic abnormalities that include central obesity, dyslipidemia, insulin resistance, and primary hypertension [8]. Similar to BPH, the prevalence of MetS steadily increases with age [9]. Xu et al. [10] have shown that metabolic disorders, including obesity and insulin resistance, can promote the development of BPH in rats consuming a high-fat diet. Another study demonstrated that the prevalence of BPH is higher in people with MetS compared with those without MetS [6]. This has been shown to be due to insulin-related stimulation of prostate growth, induction of systemic inflammation and oxidative stress, and sex hormone alterations [6].
The endocannabinoid system (ECS) plays a crucial role in various physiological and pathological conditions, such as analgesia, inflammation, cancer, MetS, and others. The ECS consists of the human cannabinoid 1 receptor (CB1) and cannabinoid 2 receptor (CB2), endogenous lipid-signaling molecules (endocannabinoids), primarily 2-arachidonoylglycerol (2-AG) and anandamide (AEA), as well as the enzymes that synthesize and degrade endocannabinoids. While CB1 is abundantly expressed in the central nervous system, CB2 is found mainly in immune cells [11, 12]. In addition, CB1 is peripherally expressed in several tissues, such as the human prostate. Specifically, CB1 is present on the human prostate epithelial layer and the sensory nerves that innervate the human prostatic stroma [13, 14]. Furthermore, the human prostate expresses the enzyme fatty acid amidohydrolase, which hydrolyzes AEA [13]. The expression of ECS components in prostatic tissue indicates that this system may influence normal prostate physiology. It has been suggested that the ECS may play a role in the pathogenesis of BPH [15]. One study suggested that antagonism of the CB1 receptor with rimonabant (SR141716) may be a useful and effective method for the prevention and treatment of BPH by reducing the size of a noncancerous hypertrophied prostate [16]. Therefore, more research is needed to fully understand the important role of ECS blockade using different modulators in the prevention and treatment of BPH.
The correlation between MetS and BPH has offered new potential targets for the treatment and prevention of both conditions. In this regard, selective inhibition of CB1 has shown promising therapeutic results in obesity-related metabolic disorders [17]. Rimonabant was the first CB1-selective antagonist/inverse agonist approved for the treatment of obesity and MetS [18]. However, in 2008, rimonabant was withdrawn due to adverse psychiatric side effects, including suicide attempts, anxiety, and depression, resulting from CB1 antagonism in the central nervous system (CNS) [19]. To prevent the adverse effects of CB1 antagonism in the CNS, different strategies to design a peripherally restricted CB1 antagonist (AM6545) and a neutral CB1 antagonist (AM4113) have been developed in this laboratory [20–24]. We recently showed that AM6545 and AM4113 attenuated peripheral IR in rats with MetS. Additionally, they exerted anti-hyperuricemia, anti-dyslipidemia, and anti-inflammatory effects [25, 26].
Therefore, the current study aimed to investigate whether peripheral blockade of CB1 might be useful in preventing MetS-related BPH. For that, a concentrated 20% w/v fructose solution and a high-salt diet as food pellets were used for eight weeks to establish a rat model of MetS associated with BPH. The CB1 antagonists AM6545 and AM4113 were administered to MetS rats to examine the effect of CB1 blockage on prostate structure and function.
Materials and methods
Chemicals
The CB1 antagonists AM4113 (5-(4-alkylphenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide) and AM6545 (5-(4-[4-cyanobut-1-ynyl]phenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(1,1-dioxo-thiomorpholino)-1H-pyrazole-3-carboxamide) were synthesized in our laboratory at the Center for Drug Discovery at Northeastern College in Boston, MA, USA, as described previously [20, 27]. Fructose and sodium chloride salt were purchased from Sigma-Aldrich (St. Louis, MO, USA). AM6545 is a peripherally acting CB1 neutral antagonist (the first neutral peripherally acting neutral antagonist). On the other hand, AM4113 is also a neutral antagonist, but unlike AM6545, it enters the brain. AM4113 is more lipid soluble and therefore should have better penetration into prostate tissue than AM6545.
Animals
Forty-eight male Wistar rats (45 days old and 150–190 g body weight) were procured from King Abdulaziz University (KSA) to model the fructose-induced MetS as in our previous published work [25]. There were no significant differences in the baseline body weights of the animals. Rats were housed in a temperature-controlled room (23 ± 1 ∘C) with a 12-h light/dark cycle. Prior to the experiment, animals were fed standard rat chow ad libitum and had unlimited access to water for seven days.
Body and prostate weight
After dissection, the weight of the prostate of each rat was recorded. Relative prostate weight was calculated by dividing the prostate weight (g) by the body weight of the rat (g) and then multiplying by 103 [29].
Prostate homogenates
Prostate specimens were homogenized by the ULTRA-TURRAX® homogenizer using a homogenization buffer (1% Triton X 100 + phosphate buffer saline, pH 7.4). Centrifugation of the homogenates for 20 min at 4000× and 4 ∘C was then performed. The supernatant was collected and kept at —80 ∘C for subsequent analysis [30].
Histological examination of the prostate
To prepare for sectioning, formalin-fixed prostate samples were routinely processed and embedded in paraffin blocks. Five micrometer (5 µm) thick paraffin sections were obtained for staining. Hematoxylin and eosin (H&E) staining was used to examine histological architecture. At least three of the stained sections from each rat were examined by electric light microscopy (Nikon Eclipse TE2000-U, NIKON, Japan), and the height of the prostate glandular epithelium was determined by Image J software (1.46a, NIH, USA).
Immunohistochemical staining for cyclin D1 detection
Immunohistochemical detection of the proliferation marker cyclin D1 was performed on prostate sections kept in paraffin. The tissue sections were dried, deparaffinized, and rehydrated in ethanol. The sections were then boiled for 5 min in a 10 mM sodium citrate buffer (pH 6.0) for 5 min, washed with phosphate-buffered saline, and immunostained. Afterward, the sections were kept for 2 h at room temperature in 5% bovine serum albumin (BSA) in tris-buffered saline (TBS). This was followed by overnight incubation with 1 µg/mL rabbit polyclonal anti-cyclin D1 primary antibody at 4 ∘C (ABCAM, Cambridge, UK). Slides were washed the next day with TBS before being kept with the biotinylated secondary antibody using the Cell and Tissue Staining Kit (R&D Systems, MN, USA). A light microscope was used to examine the slides. Photomicrographs were taken with a CCD camera and quantified using ImageJ software (ImageJ, 1.46a, NIH, USA) [31].
Measurement of oxidative stress markers
According to the manufacturer’s instructions, kits purchased from Biodiagnostics (Cairo, Egypt) were used to determine the concentrations of malondialdehyde (MDA, product no. MD-252), superoxide dismutase (SOD, product no. SD-252), and catalase (CAT, product no. CA-2516) in prostate homogenates.
Endocannabinoid measurements
According to the manufacturer’s instructions, Real-Gene Labs (Lake Forest, CA, USA) kits were used to measure endocannabinoids AEA and 2-AG in prostate homogenates.
Measurements of inflammatory markers
An enzyme-linked immunosorbent assay (ELISA) was performed to measure the concentrations of interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α) in prostate tissue homogenates (ab234570, ab100785, ABCAM UK, respectively). Quantification was performed using an automated ELISA reader.
Ethical statement
All experimental animal procedures were performed at King Abdulaziz University according to the “Guidelines for Animal Care and Treatment of the Biomedical Ethics Research Committee” (Reference No. 479-16). Every effort was made to keep animal suffering to a minimum and reduce the number of animals used.
Statistical analysis
All data are presented as means ± standard deviation (S.D.). GraphPad Prism (Version 9) was used to analyze the different groups using one-way analysis of variance (ANOVA) and Tukey’s post hoc test for multiple comparisons. P < 0.05 was used to indicate statistical significance.
Results
Body and prostate weight
Treatment of rats with AM6545 (A65 group) or AM4113 (A41 group) alone did not adversely affect prostate weights (P > 0.05) relative to the controls (Table 1). However, fructose solution and high-salt food pellets fed (MetS group) rats significantly increased relative prostate weight by 67% compared with controls (P < 0.05). Importantly, administration of AM6545 (MetS + A65 group) or AM4113 (MetS + A41 group) to MetS rats significantly decreased relative prostate weight by approximately 26% or 30%, respectively (P < 0.05).
| Prostate weight (g) | Body weight (g) | Relative prostate weight (×103) | |
|---|---|---|---|
| Control | 0.25 ± 18.3 | 260.3 ± 22.1 | 0.96 ± 0.07 |
| A65 | 0.24 ± 20.1 | 254.0 ± 21.7 | 0.94 ± 0.12 |
| A41 | 0.27 ± 19.5 | 259.3 ± 20.8 | 1.04 ± 0.01 |
| MetS | 0.64 ± 55.3 | 380.1 ± 31.1 | 1.68 ± 0.02a,b,c |
| MetS + A65 | 0.42 ± 33.5 | 343.4 ± 28.2 | 1.22 ± 0.04a,b,c,d |
| MetS + A41 | 0.37 ± 30.1 | 325.3 ± 27.1 | 1.13 ± 0.18a,b,d |
Histological examination of the prostate
Histopathology of the control group (Figure 1A) and the groups that received AM6545 (Figure 1B) and AM4113 (Figure 1C) showed normal histoarchitecture with well-defined glandular structures, single-layered epithelial cells lining the ductules, well-differentiated stroma and well-defined interductal spaces. After eight weeks of sustained fructose and salt feeding, marked histological changes occurred in the prostatic ductules and interstitial tissue in the MetS group. The prostatic ductules showed dilated lumens, irregular boundaries, enlarged luminal epithelium, and scanty secretion (Figure 1D). The interductal spaces became wider and filled with interstitial tissue. The luminal epithelium was greatly increased in height (Figure S1). Treatment of rats with AM6545 and AM4113 (Figure 1E and 1F) induced a dramatic improvement in the histologic profile of the prostate, which was almost similar to the control ones. Prostatic ductules restored their normal outline. The luminal epithelium had normal heights, and marked epithelial folds protruded into the ductal lumens. The interductal spaces were greatly reduced reaching normal spacing; the prostatic stroma appeared crowded with ductules and interductal spaces. The height of the luminal epithelium in the different experimental groups is shown in Figure 1G. The groups treated with AM6545 or AM4113 did not show any changes compared with the control group. However, there was a marked increase in epithelial heights by 300% in the MetS group relative to controls. The epithelial heights in MetS rats cotreated with AM6545 and AM4113 were significantly decreased by 30% and 52%, respectively, compared with MetS rats.
Cyclin D1 assessment as a proliferation marker
Immunohistochemical analysis of the expression of cyclin D1 protein as a proliferation marker revealed a moderate amount of stained cells in the control groups (Figure 2A–2C). On the other hand, an increase in stained cells was observed in the MetS group, indicating an increase in the proliferation rate (Figure 2D). Treatment of MetS rats with AM6545 or AM4113 significantly reduced cyclin D1-positive cells compared with MetS rats (Figure 2E and 2F). Densitometric analysis of cyclin D1-positive cells indicated that AM6545 and AM4113 reduced cyclin D1 expression by 26% and 54%, respectively (Figure 2G).
Assessment of prostate oxidative stress markers
To assess the effects of AM6545 and AM4113 treatments on oxidative stress in the prostate, measurements of MDA as a lipid peroxidation marker as well as SOD and CAT activities in prostatic tissues were performed. The CB1 antagonist groups (A65 or A41 groups) did not cause changes in the measured oxidative stress markers (Table 2). On the other hand, MetS rats showed a significant increase in the concentration of MDA in prostate tissue by 736% compared with controls. Administration of AM6545 (MetS + A65 group) or AM4113 (MetS + A41 group) to MetS rats caused a marked lowering of MDA concentrations by 33% and 68%, respectively, compared with MetS rats. Post hoc analysis demonstrated that MDA reduction in the MetS + A41 group was superior to that in the MetS + A65 group (P < 0.05). However, the activities of the antioxidant enzymes SOD and CAT were decreased by 40% and 33%, respectively, in the prostate tissue of the MetS rats compared with the control group. Administration of AM6545 or AM4113 markedly ameliorated the reduction of SOD activity and increased it by 34% after AM6545 and by 41% after AM4113 relative to the MetS group. Similarly, CAT activity increased by 46% upon treatment with both CB1 antagonists. Therefore, the antioxidant activity of AM6545 and AM4113 might be responsible for their protective effects on MetS-induced BPH in rats.
| MDA (nmol/mg protein) | SOD (U/mg protein) | CAT (U/mg protein) | |
|---|---|---|---|
| Control | 0.39 ± 0.04 | 12.1 ± 0.9 | 66.4 ± 5.2 |
| A65 | 0.40 ± 0.05 | 11.9 ± 1.0 | 62.8 ± 5.4 |
| A41 | 0.41 ± 0.05 | 12.4 ± 1.1 | 63.2 ± 5.8 |
| MetS | 3.26 ± 0.31a,b,c | 7.3 ± 0.6a,b,c | 44.7 ± 4.1a,b,c |
| MetS + A65 | 2.21 ± 0.23a,b,c,d | 9.8 ± 0.9a,b,c,d | 65.6 ± 5.3d |
| MetS + A41 | 1.07 ± 0.11a,b,c,d,e | 10.3 ± 1.1a,b,c,d | 65.3 ± 4.8d |
Assessment of TNF-α and IL-6 in prostatic tissue
The anti-inflammatory activity of the CB1 antagonists AM6545 and AM4113 in MetS-induced BPH was explored. Controls had low concentrations of TNF-α and IL-6 (Figure 3). Treatment of control rats with AM6545 or AM4113 alone did not change the concentration of these inflammatory markers. However, TNF-α and IL-6 levels were significantly increased by 167% and 176%, respectively, in the prostate tissues of MetS rats relative to controls. Treatment of MetS rats with AM6545 or AM4113 (10 mg/kg) significantly decreased TNF-α by 24% and 46%, respectively, and IL-6 by 24% and 37%, respectively (P < 0.05).
Measurement of the prostate content of anandamide (AEA) and 2-arachidonoyl glycerol (2-AG)
To assess endocannabinoid activity in the prostate of MetS rats, concentrations of the endogenous cannabinoids AEA and 2-AG were measured in prostate homogenates. No change in the concentration of prostatic AEA and 2-AG was observed in control rats treated with either AM6545 (A65 group) or AM4113 (A41 group) (Figure 4). However, AEA and 2-AG contents were markedly increased in the prostates of MetS rats by 118% and 93%, respectively, compared with the controls. Treatment of MetS rats with AM6545 (MetS + A65 group) or AM4113 (MetS + A41 group) significantly reduced the concentration of AEA by 21% and 38% and of 2-AG by 13% and 25% in the prostate relative to the MetS group. Post hoc analysis demonstrated that the reduction of AEA was more significant in animals in the MetS + A41 group than in the MetS + A65 group (P < 0.05).
Discussion
BPH is a common medical condition that affects men as they age and is strongly associated with MetS. This noncancerous enlargement of the prostate gland significantly compromises the outflow of urine from the bladder, leading to several symptoms such as urinary retention. Increased expression of CB1 has been found in BPH and prostate cancer tissue, highlighting the therapeutic potential of targeting this receptor in these diseases [32–34]. However, CB1 is also highly expressed in the CNS. Hence, targeting this receptor has been associated with severe psychiatric side effects, including depression, anxiety, and suicide attempts [19]. Selective targeting of CB1 in the periphery is a promising therapeutic strategy for managing BPH. This work aimed to evaluate the therapeutic potential of the peripheral CB1 antagonists AM6545 and AM4113 in the treatment of BPH in rats.
In the present study, rats were maintained on a high-salt diet and high-fructose drinking water to create a MetS rat model. The accumulation of visceral fat, increased body weight, insulin resistance, dyslipidemia, and increased mean arterial blood pressure indicated the development of MetS, as previously reported [35]. Most MetS symptoms were mitigated by the CB1 antagonists AM6545 or AM4113. These findings are consistent with our previously published work [25]. Similarly, the peripherally restricted CB1 antagonists JD-5006 and JD-5037 enhanced glucose tolerance and insulin sensitivity [36]. Additionally, these drugs improve fatty liver and dyslipidemia while normalizing body weight and MetS in a mouse model of obesity [37, 38]. The results support the hypothesis that blocking peripheral CB1 receptors is adequate to achieve the most beneficial metabolic effects of globally acting CB1.
Furthermore, BPH was observed along with MetS, as shown by a significant increase in prostate weight. Histological examination of the prostate revealed marked pathological changes in the prostatic ductules marked by a substantial rise in the prostate glandular epithelial height, which is consistent with previous studies [10]. The CB1 antagonists AM6545 and AM4113 prevented these pathological changes in prostate weight and histology. Our findings are consistent with an earlier study that reported that CB1 antagonist help prevent or treat BPH by reducing the size of a noncancerous hypertrophied prostate [16]. The observed effects of CB1 antagonists AM6545 or AM4113 against MetS-induced prostate hyperplasia might be attributed to their antiproliferative properties, as shown by the suppression of cyclin D1 expression. These results are consistent with the known antiproliferative properties of the selective CB1 antagonist rimonabant [39]. Rimonabant has previously been reported to inhibit the proliferation of human peripheral blood mononuclear cells [40] and human breast cancer cells [39] by blocking the Gi/S phase of the cell cycle and decreasing cyclin D expression. The cell cycle blockade induced by CB1 antagonists is due to CB1 receptor inhibition rather than nonspecific effects. Activation of CB1 receptors has been shown to stimulate the PI3K/AKT/mTOR signaling pathway, leading to increased cell proliferation, whereas rimonabant attenuates this signaling pathway resulting in cell cycle arrest [41]. Additionally, the CB1 receptor has been reported to activate the Wnt/β-catenin pathway, which regulates cell cycle progression and proliferation in cancer cells. Inhibition of Wnt/β-catenin pathway by rimonabant was reported in colorectal cancer cells, leading to cell cycle arrest [42]. Therefore, peripheral targeting of CB1 by AM6545 and AM4113 is a promising therapeutic strategy in BPH treatment without the side effects associated with rimonabant that stems from the central CB1 blockade [19].
It has been suggested that oxidative stress has a role in the pathophysiology of MetS [41]. Our observations, consistent with earlier research, demonstrated that MetS exacerbated oxidative stress in the prostate, as shown by the accumulation of MDA and the reduction in the activities of CAT and SOD [42]. Both AM6545 and AM4113 exhibited antioxidant activities, even though AM4113 was significantly more effective in attenuating the increase in MDA content associated with BPH in MetS. Thus, the beneficial effects of AM6545 and AM4113 in this study could be partly due to their significant antioxidant activities. These results are consistent with reports in the literature indicating that CB1 activation is linked to oxidative stress and inflammation [43–45]. The exact signaling pathways involved in the antioxidant activities of AM6545 and AM4113 have not yet been fully elucidated. However, a study by Chang et al. reported that blocking CB1 receptors ammeliorated hepatic inflammation and oxidative stress in a rat model of severely uncontrolled diabetes. These protective effects of rimonabant were mediated through increased activity of the Nrf2-AMPK signaling pathway, a critical regulator of the cellular antioxidant defense shield [43]. Hence, blocking CB1 in prostate tissue would have the potential to alleviate oxidative stress and inflammation in MetS-associated BPH.
Prostatic inflammation is an essential factor that influences the development of BPH, particularly with MetS, because this syndrome is pathologically characterized by systemic inflammation [46]. Previous studies have reported the anti-inflammatory effects of AM6545 and AM4113 in MetS rat models [25, 47]. In the current study, AM6545 and AM4113 exhibited vigorous anti-inflammatory activities, as both agents significantly ameliorated the increase in the expression of the proinflammatory mediators TNF-α and IL-6 found in the MetS group. In accordance with these results, blockade of CB1 in adipose and liver tissues was found to attenuate the secretion of inflammatory cytokines and activation of M1 macrophages in rats [48, 49]. Hence, these results confirm that prostatic inflammation could be targeted using CB1 antagonists such as AM6545 and AM4113 as a therapeutic intervention for the BPH treatment.
The ECS has been shown to be dysregulated in many conditions, including obesity and MetS. An increase in 2-AG levels, but not AEA, has been reported in the plasma of patients with MetS [50, 51]. In our recent study, we found an elevation in the endocannabinoid activity in the liver, as indicated by an increase in liver AEA and 2-AG concentrations in the high-fructose/high-salt rat model of MetS [25]. Similarly, an increase in AEA and 2-AG concentrations was observed in the prostate of the MetS-induced BPH rat model. However, AM6545 and AM4113 treatments decreased AEA and 2-AG contents in the prostate. The reduction in AEA and 2-AG levels by CB1 antagonism is proposed due to the negative feedback regulation of endocannabinoid synthesis by CB1 receptor activation. However, when CB1 receptors are blocked, the feedback loop is disrupted, and AEA and 2-AG decrease. This effect has been observed in various settings, including in animal models of obesity and metabolic disorders in addition to clinical trials of CB1 antagonists. The reduction in endocannabinoid levels is believed to mediate the beneficial effects of CB1 antagonism on cardiovascular and metabolic health. In addition, the decrease in endocannabinoid levels may attenuate CB2-mediated signaling in prostatic tissue, where CB2 receptors are expressed and have been shown to regulate prostate growth and inflammation. However, additional research is required to determine the exact contribution of CB2 receptors to the observed effects. Overall, these findings indicate that dysregulation of endocannabinoids in the prostate might contribute to the pathology of MetS-induced BPH, which can be normalized by blocking the CB1 receptor by peripherally acting antagonists.
In addition to the direct inhibition of CB1 receptors in the prostate, it is indeed possible that improvements in blood glucose levels or other metabolic parameters (such as glucose and lipid levels) may have contributed to the observed reduction in BPH. Preclinical studies have demonstrated that inhibition of CB1 receptors can improve metabolic parameters in animal models of MetS [18]. Therefore, it is possible that the observed reduction in BPH in the MetS group may be due to a combination of direct CB1 receptor inhibition in the prostate and improvements in metabolic parameters. Further research is needed to fully elucidate the underlying mechanisms and determine whether CB1 receptor inhibition alone can reduce BPH.
Conclusion
The CB1 antagonists AM6545 and AM4113 protect against MetS-induced BPH in rats. AM6545 and AM4113 exhibited antiproliferative, antioxidant, and anti-inflammatory effects in the prostate. AM4113 exhibited superior anti-proliferative and antioxidant properties compared to AM6545. This may be attributed to its superior lipid solubility compared to AM6545, which gives it higher permeability to prostate tissue.
Supplemental Data
Acknowledgments
This paper was funded by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, under Grant No. 3-166-36-HiCi. The authors, therefore, acknowledge with thanks DSR technical and financial support.
Footnotes
Footnote Group
References
Untitled section
References
- 1.Madersbacher S, Sampson N, Culig Z. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a mini-review. Gerontology. 2019;65(5):458–64. doi: 10.1159/000496289. https://doi.org/10.1159/000496289.
- 2.Lloyd GL, Marks JM, Ricke WA. Benign prostatic hyperplasia and lower urinary tract symptoms: what is the role and significance of inflammation? Curr Urol Rep. 2019;20(9):54. doi: 10.1007/s11934-019-0917-1. https://doi.org/10.1007/s11934-019-0917-1.
- 3.Bellinger AS, Elliott SP, Yang L, Wei JT, Saigal CS, Smith A, et al. Changes in initial expenditures for benign prostatic hyperplasia evaluation in the medicare population: a comparison to overall medicare inflation. J Urol. 2012 May;187(5):1739–46. doi: 10.1016/j.juro.2011.12.079. https://doi.org/10.1016/j.juro.2011.12.079.
- 4.Moul S, McVary KT. Lower urinary tract symptoms, obesity and the metabolic syndrome. Curr Opin Urol. 2010 Jan;20(1):7–12. doi: 10.1097/MOU.0b013e3283336f3f. https://doi.org/10.1097/MOU.0b013e3283336f3f.
- 5.Jiang M, Strand DW, Franco OE, Clark PE, Hayward SW. PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia. Differentiation. 2011 Nov-Dec;82(4–5):220–36. doi: 10.1016/j.diff.2011.05.008. https://doi.org/10.1016/j.diff.2011.05.008.
- 6.Vignozzi L, Gacci M, Maggi M. Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. Nat Rev Urol. 2016 Feb;13(2):108–19. doi: 10.1038/nrurol.2015.301. https://doi.org/10.1038/nrurol.2015.301.
- 7.Ngai H-Y, Yuen K-KS, Ng C-M, Cheng C-H, Chu S-KP. Metabolic syndrome and benign prostatic hyperplasia: an update. Asian J Urol. 2017 Jul;4(3):164–73. doi: 10.1016/j.ajur.2017.05.001. https://doi.org/10.1016/j.ajur.2017.05.001.
- 8.Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Ther Adv Cardiovasc Dis. 2017 Aug;11(8):215–25. doi: 10.1177/1753944717711379. https://doi.org/10.1177/1753944717711379.
- 9.Churilla JR, Fitzhugh EC, Thompson DL. The metabolic syndrome: how definition impacts the prevalence and risk in U.S. adults: 1999–2004 NHANES. Metab Syndr Relat Disord. 2007 Dec;5(4):331–42. doi: 10.1089/met.2007.0010. https://doi.org/10.1089/met.2007.0010.
- 10.Xu C, Xu Y, Shen Z, Zhou H, Xiao J, Huang T. Effects of metformin on prostatic tissue of rats with metabolic syndrome and benign prostatic hyperplasia. Int Urol Nephrol. 2018 Apr;50(4):611–7. doi: 10.1007/s11255-018-1826-9. https://doi.org/10.1007/s11255-018-1826-9.
- 11.Gérard C, Mollereau C, Vassart G, Parmentier M. Nucleotide sequence of a human cannabinoid receptor cDNA. Nucl Acids Res. 1990;18(23):7142–2. doi: 10.1093/nar/18.23.7142. https://doi.org/10.1093/nar/18.23.7142.
- 12.Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA. 1990 Mar;87(5):1932–6. doi: 10.1073/pnas.87.5.1932. https://doi.org/10.1073/pnas.87.5.1932.
- 13.Ruiz-Llorente L, Sánchez MG, Carmena MJ, Prieto JC, Sánchez-Chapado M, Izquierdo A, et al. Expression of functionally active cannabinoid receptor CB1 in the human prostate gland: cannabinoid receptors in prostate gland. Prostate. 2003 Feb;54(2):95–102. doi: 10.1002/pros.10165. https://doi.org/10.1002/pros.10165.
- 14.Gratzke C, Weinhold P, Reich O, Seitz M, Schlenker B, Stief CG, et al. Transient receptor potential a1 and cannabinoid receptor activity in human normal and hyperplastic prostate: relation to nerves and interstitial cells. Eur Urol. 2010 May;57(5):902–10. doi: 10.1016/j.eururo.2009.08.019. https://doi.org/10.1016/j.eururo.2009.08.019.
- 15.Ventura S, Oliver V, White C, Xie J, Haynes J, Exintaris B. Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH) Br J Pharmacol. 2011 Jul;163(5):891–907. doi: 10.1111/j.1476-5381.2011.01332.x. https://doi.org/10.1111/j.1476-5381.2011.01332.x.
- 16.Croci T, Guagnini F, Avallone R. Use of a cannabinoid CB1 receptor antagonist for preparation of drugs useful for the prevention and treatment of benign prostatic hypertrophy. EP2037920A1. 2009 Available from: https://patents.google.com/patent/EP2037920A1/en.
- 17.Janero DR, Makriyannis A. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin Emerg Drugs. 2009 Mar;14(1):43–65. doi: 10.1517/14728210902736568. https://doi.org/10.1517/14728210902736568.
- 18.Gadde KM, Allison DB. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. Circulation. 2006 Aug;114(9):974–84. doi: 10.1161/CIRCULATIONAHA.105.596130. https://doi.org/10.1161/CIRCULATIONAHA.105.596130.
- 19.Koch M. Cannabinoid receptor signaling in central regulation of feeding behavior: a mini-review. Front Neurosci. 2017 May;11:293. doi: 10.3389/fnins.2017.00293. https://doi.org/10.3389/fnins.2017.00293.
- 20.Cluny NL, Vemuri VK, Chambers AP, Limebeer CL, Bedard H, Wood JT, et al. A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharmacol. 2010 Oct;161(3):629–42. doi: 10.1111/j.1476-5381.2010.00908.x. https://doi.org/10.1111/j.1476-5381.2010.00908.x.
- 21.Tam J, Vemuri VK, Liu J, Bátkai S, Mukhopadhyay B, Godlewski G, et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest. 2010 Aug;120(8):2953–66. doi: 10.1172/JCI42551. https://doi.org/10.1172/JCI42551.
- 22.Cluny NL, Chambers AP, Vemuri VK, Wood JT, Eller LK, Freni C, et al. The neutral cannabinoid CB1 receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat. Pharmacol Biochem Behav. 2011 Jan;97(3):537–43. doi: 10.1016/j.pbb.2010.10.013. https://doi.org/10.1016/j.pbb.2010.10.013.
- 23.Gueye AB, Pryslawsky Y, Trigo JM, Poulia N, Delis F, Antoniou K, et al. The CB1 neutral antagonist AM4113 retains the therapeutic efficacy of the inverse agonist rimonabant for nicotine dependence and weight loss with better psychiatric tolerability. Int J Neuropsychopharmacol. 2016 Dec;19(12):pyw068. doi: 10.1093/ijnp/pyw068. https://doi.org/10.1093/ijnp/pyw068.
- 24.Ma H, Zhang G, Mou C, Fu X, Chen Y. Peripheral CB1 receptor neutral antagonist, AM6545, ameliorates hypometabolic obesity and improves adipokine secretion in monosodium glutamate induced obese mice. Front Pharmacol. 2018 Mar;9:156. doi: 10.3389/fphar.2018.00156. https://doi.org/10.3389/fphar.2018.00156.
- 25.Eid BG, Neamatallah T, Hanafy A, El-Bassossy HM, Aldawsari HM, Vemuri K, et al. Effects of the CB1 receptor antagonists AM6545 and AM4113 on insulin resistance in a high-fructose high-salt rat model of metabolic syndrome. Medicina. 2020 Oct;56(11):573. doi: 10.3390/medicina56110573. https://doi.org/10.3390/medicina56110573.
- 26.Eid BG, Neamatallah T, Hanafy A, El-Bassossy HM, Binmahfouz L, Aldawsari HM, et al. Interference with TGFβ1-mediated inflammation and fibrosis underlies reno-protective effects of the CB1 receptor neutral antagonists AM6545 and AM4113 in a rat model of metabolic syndrome. Molecules. 2021 Feb;26(4):866. doi: 10.3390/molecules26040866. https://doi.org/10.3390/molecules26040866.
- 27.Sink KS, McLaughlin PJ, Wood JAT, Brown C, Fan P, Vemuri VK, et al. The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology. 2008 Mar;33(4):946–55. doi: 10.1038/sj.npp.1301476. https://doi.org/10.1038/sj.npp.1301476.
- 28.Parasuraman S, Christapher PV. Anesthesia and euthanasia of experimental animals. In: Lakshmanan M, Shewade DG, Raj GM, editors. Introduction to basics of pharmacology and toxicology: volume 3 : experimental pharmacology : research methodology and biostatistics. Singapore: Springer Nature; 2022. p. 65-75. https://doi.org/10.1007/978-981-19-5343-9_5.
- 29.Eid BG, Abdel-Naim AB. Piceatannol attenuates testosterone-induced benign prostatic hyperplasia in rats by modulation of Nrf2/HO-1/NFκB axis. Front Pharmacol. 2020 Dec;11:614897. doi: 10.3389/fphar.2020.614897. https://doi.org/10.3389/fphar.2020.614897.
- 30.Kmiec Z. Histological and histochemical methods: theory and practice. 5th edition, Scion Publishing, 2015, 571 pp. Folia Histochemica et Cytobiologica. 2016 May;54:58–9. https://doi.org/10.5603/FHC.a2016.0007.
- 31.Prasad K, Prabhu GK. Image analysis tools for evaluation of microscopic views of immunohistochemically stained specimen in medical research-a review. J Med Syst. 2012 Aug;36(4):2621–31. doi: 10.1007/s10916-011-9737-7. https://doi.org/10.1007/s10916-011-9737-7.
- 32.Chung SC, Hammarsten P, Josefsson A, Stattin P, Granfors T, Egevad L, et al. A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. Eur J Cancer. 2009 Jan;45(1):174–82. doi: 10.1016/j.ejca.2008.10.010. https://doi.org/10.1016/j.ejca.2008.10.010.
- 33.Czifra G, Varga A, Nyeste K, Marincsák R, Tóth BI, Kovács I, et al. Increased expressions of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate carcinoma. J Cancer Res Clin Oncol. 2009 Apr;135(4):507–14. doi: 10.1007/s00432-008-0482-3. https://doi.org/10.1007/s00432-008-0482-3.
- 34.Cipriano M, Häggström J, Hammarsten P, Fowler CJ. Association between cannabinoid CB1 receptor expression and Akt signalling in prostate cancer. PLoS One. 2013;8(6):e65798. doi: 10.1371/journal.pone.0065798. https://doi.org/10.1371/journal.pone.0065798.
- 35.Abdelhedi O, Khemakhem H, Nasri R, Jridi M, Mora L, Ben Amor I, et al. Assessment of cholesterol, glycemia control and short- and long-term antihypertensive effects of smooth hound viscera peptides in high-salt and fructose diet-fed wistar rats. Marine Drugs. 2019 Mar;17(4):194. doi: 10.3390/md17040194. https://doi.org/10.3390/md17040194.
- 36.Chorvat RJ, Berbaum J, Seriacki K, McElroy JF. JD-5006 and JD-5037:peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities. Bioorg Med Chem Lett. 2012 Oct;22(19):6173–80. doi: 10.1016/j.bmcl.2012.08.004. https://doi.org/10.1016/j.bmcl.2012.08.004.
- 37.Tam J, Vemuri VK, Liu J, Bátkai S, Mukhopadhyay B, Godlewski G, et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest. 2010 Aug;120(8):2953–66. doi: 10.1172/JCI42551. https://doi.org/10.1172/JCI42551.
- 38.Knani I, Earley BJ, Udi S, Nemirovski A, Hadar R, Gammal A, et al. Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader–Willi syndrome. Mol Metab. 2016 Dec;5(12):1187–99. doi: 10.1016/j.molmet.2016.10.004. https://doi.org/10.1016/j.molmet.2016.10.004.
- 39.Santoro A, Pisanti S, Grimaldi C, Izzo AA, Borrelli F, Proto MC, et al. Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colon. Int J Cancer. 2009 Sep;125(5):996–1003. doi: 10.1002/ijc.24483. https://doi.org/10.1002/ijc.24483.
- 40.Malfitano AM, Laezza C, Pisanti S, Gazzerro P, Bifulco M. Rimonabant (SR141716) exerts anti-proliferative and immunomodulatory effects in human peripheral blood mononuclear cells: rimonabant is an immunomodulatory drug. Br J Pharmacol. 2008 Mar;153(5):1003–10. doi: 10.1038/sj.bjp.0707651. https://doi.org/10.1038/sj.bjp.0707651.
- 41.Rani V, Deep G, Singh RK, Palle K, Yadav UCS. Oxidative stress and metabolic disorders: pathogenesis and therapeutic strategies. Life Sci. 2016 Mar;148:183–93. doi: 10.1016/j.lfs.2016.02.002. https://doi.org/10.1016/j.lfs.2016.02.002.
- 42.Aljehani AA, Albadr NA, Nasrullah MZ, Neamatallah T, Eid BG, Abdel-Naim AB. Icariin ameliorates metabolic syndrome-induced benign prostatic hyperplasia in rats. Environ Sci Pollut Res. 2022 Mar;29(14):20370–8. doi: 10.1007/s11356-021-17245-4. https://doi.org/10.1007/s11356-021-17245-4.
- 43.Chang E, Kim DH, Yang H, Lee DH, Bae SH, Park CY. CB1 receptor blockade ameliorates hepatic fat infiltration and inflammation and increases Nrf2-AMPK pathway in a rat model of severely uncontrolled diabetes. PLoS One. 2018 Oct;13(10):e0206152. doi: 10.1371/journal.pone.0206152. https://doi.org/10.1371/journal.pone.0206152.
- 44.Mukhopadhyay P, Rajesh M, Bátkai S, Patel V, Kashiwaya Y, Liaudet L, et al. CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. Cardiovasc Res. 2010 Mar;85(4):773–84. doi: 10.1093/cvr/cvp369. https://doi.org/10.1093/cvr/cvp369.
- 45.Rajesh M, Bátkai S, Kechrid M, Mukhopadhyay P, Lee WS, Horváth B, et al. Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy. Diabetes. 2012 Mar;61(3):716–27. doi: 10.2337/db11-0477. https://doi.org/10.2337/db11-0477.
- 46.Robert G, Descazeaud A, Nicolaïew N, Terry S, Sirab N, Vacherot F, et al. Inflammation in benign prostatic hyperplasia: a 282 patients’ immunohistochemical analysis. Prostate. 2009 Dec;69(16):1774–80. doi: 10.1002/pros.21027. https://doi.org/10.1002/pros.21027.
- 47.Ma H, Zhang G, Mou C, Fu X, Chen Y. Peripheral CB1 receptor neutral antagonist, AM6545, ameliorates hypometabolic obesity and improves adipokine secretion in monosodium glutamate induced obese mice. Front Pharmacol. 2018;9:156. doi: 10.3389/fphar.2018.00156. https://doi.org/10.3389/fphar.2018.00156.
- 48.Mehrpouya-Bahrami P, Chitrala KN, Ganewatta MS, Tang C, Murphy EA, Enos RT, et al. Blockade of CB1 cannabinoid receptor alters gut microbiota and attenuates inflammation and diet-induced obesity. Sci Rep. 2017 Nov;7(1):15645. doi: 10.1038/s41598-017-15154-6. https://doi.org/10.1038/s41598-017-15154-6.
- 49.Tian L, Li W, Yang L, Chang N, Fan X, Ji X, et al. Cannabinoid receptor 1 participates in liver inflammation by promoting M1 macrophage polarization via RhoA/NF-κB p65 and ERK1/2 pathways, respectively, in mouse liver fibrogenesis. Front Immunol. 2017;8:1214. doi: 10.3389/fimmu.2017.01214. https://doi.org/10.3389/fimmu.2017.01214.
- 50.Blüher M, Engeli S, Klöting N, Berndt J, Fasshauer M, Bátkai S, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes. 2006 Nov;55(11):3053–60. doi: 10.2337/db06-0812. https://doi.org/10.2337/db06-0812.
- 51.Côté M, Matias I, Lemieux I, Petrosino S, Alméras N, Després JP, et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes. 2007 Apr;31(4):692–9. doi: 10.1038/sj.ijo.0803539. https://doi.org/10.1038/sj.ijo.0803539.